Is Levocabastine registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 2 valid registrations of Levocabastine, including LIVOSTIN EYE DROPS 0.5MG-ML (0.5 mg/ml, Eye drops, suspension, SAR 36.00); LIVOSTIN NASAL SPRAY 0.5MG-ML (0.5 mg/ml, Nasal spray, suspension, SAR 33.60).

Is Levocabastine approved by the US FDA?

Drugs@FDA lists 1 application product line for Levocabastine, including LIVOSTIN (Discontinued).

Active substance

Levocabastine

SFDA 2
US FDA 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
LIVOSTIN EYE DROPS 0.5MG-ML	0.5 mg/ml	Eye drops, suspension · Ophthalmic use	1 Dropper Container	SAR 36.00	NCE · OTC	JANSSEN PHARMACEUTICA N.V	Valid
LIVOSTIN NASAL SPRAY 0.5MG-ML	0.5 mg/ml	Nasal spray, suspension · Nasal use	1 Spray Container	SAR 33.60	NCE · OTC	JANSSEN PHARMACEUTICA N.V	Valid

Indications — CHI Daman Drug Formulary

ALLERGIC RHINITIS-ALLERGIC RHINO-CONJUNCTIVITIS

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
LIVOSTIN	EQ 0.05% BASE	suspension/drops · ophthalmic	NOVARTIS	Discontinued	10 Nov 1993

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.